Except for the CSF replication 3 samples, all CSF samples used in this study were collected under the auspices of the Emory ADRC or closely affiliated research institutions. In total, there were four cohorts of Emory CSF samples used in these proteomics studies. The discovery CSF cohort contained samples from 20 healthy controls and 20 patients with AD. CSF replication 1 included samples from 32 healthy controls, 31 individuals with AsymAD, and 33 individuals with AD. CSF replication 2 contained 147 control and 150 AD samples. The multidisease CSF replication 4 cohort comprised 18 control, 17 AD, 19 ALS, 13 PD, and 11 FTD samples. All Emory research participants were provided informed consent under protocols approved by the Institutional Review Board at Emory University. CSF was collected by lumbar puncture and banked according to the 2014 National Institute on Aging best practice guidelines for Alzheimer’s Disease Centers (https://alz.washington.edu/BiospecimenTaskForce.html). Control and patients with AsymAD and AD received standardized cognitive assessments in the Emory Cognitive Neurology Clinic or Goizueta ADRC and their CSF samples subjected to ELISA Aβ1–42, total tau, and p-tau analysis by the INNO-BIA AlzBio3 Luminex Assay (65 (link)). The ELISA values were used to support subject diagnostic classifications based on established AD biomarker cutoff criteria (66 (link), 67 (link)). Basic demographic and diagnostic data for other CSF diagnoses (FTD, ALS, and PD) were also obtained from the Emory ADRC or affiliated research institutions. Summarized case metadata for these Emory CSF cases can be found in table S1A. Characteristics of the Swiss CSF replication 3 cohort were previously published (45 (link)).